Cardiac surgical aiding for premature infants with patent ductus arteriosus (PDA) in the PerІnatal centre of Autonomous Republic of Crimea

2014 ◽  
Vol 4 (1(11)) ◽  
pp. 13-16
Author(s):  
I.A. Aksenova ◽  
A.I. Kvasha ◽  
B.M. B.M. Todurov ◽  
T.U. Babich ◽  
A.G. Sidorov ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Ductus Arteriosus ◽  
Autonomous Republic ◽  
Patent Ductus

Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome

2001 ◽  
Vol 138 (2) ◽  
pp. 205-211 ◽  
Author(s):  
Bart Van Overmeire ◽  
Hilde Van de Broek ◽  
Paul Van Laer ◽  
Joost Weyler ◽  
Piet Vanhaesebrouck
Keyword(s):  
Patent Ductus Arteriosus ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Premature Infants ◽  
Distress Syndrome ◽  
Ductus Arteriosus ◽  
Patent Ductus ◽  
Indomethacin Treatment

scholarly journals Low-Dose Intravenous Paracetamol for Patent Ductus Arteriosus in Indomethacin-Resistant or Contraindicated Preterm Infants: Three Cases Reports

2017 ◽  
Vol 07 (04) ◽  
pp. e230-e233 ◽  
Author(s):  
Shun Matsumura ◽  
Ayumi Oshima ◽  
Sumie Fujinuma ◽  
Kosuke Tanaka ◽  
Nobuhiko Nagano ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Ductus Arteriosus ◽  
Limited Data ◽  
Gastrointestinal Complications ◽  
Surgical Closure ◽  
Institutional Ethics ◽  
Intravenous Paracetamol ◽  
Administration Protocol ◽  
Patent Ductus

Background Although indomethacin (IND) is the standard treatment for hemodynamically significant patent ductus arteriosus (hsPDA) in Japan, it may be associated with renal impairment and gastrointestinal complications. The use of paracetamol for hsPDA closure has recently increased. Unlike IND, paracetamol does not have a peripheral vasoconstrictive effect and can be given to infants with contraindications to IND. Based on limited data available from randomized trials, paracetamol and IND seem to have similar effects. However, there have been no reports of the use of paracetamol for hsPDA in Japan. Cases Our drug administration protocol was approved by the institutional ethics committee after purchasing a clinical trial insurance. In three premature infants in whom IND was contraindicated or ineffective, a 7.5 mg/kg of paracetamol was intravenously administered every 6 hour for 3 days after obtaining parental consents. A temporary hsPDA closure was observed in two of the three infants. However, all three infants eventually needed surgical closure. No side effects, such as hepatic and renal dysfunctions, and adverse events were reported. Conclusion The intravenous administration of paracetamol was safe and feasible in premature infants with hsPDA. Future clinical trials with optimized dose and timing of administration are needed.

scholarly journals The factors associated with the efficacy of indomethacin treatment in premature infants with patent ductus arteriosus

2007 ◽  
Vol 50 (6) ◽  
pp. 531
Author(s):  
Min Jeong Yoon ◽  
Hye Sun Yoon ◽  
Sung Hoon Chung ◽  
Mi Young Han ◽  
Chong Woo Bae
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Ductus Arteriosus ◽  
Factors Associated ◽  
Patent Ductus ◽  
Indomethacin Treatment
Sign in / Sign up

Export Citation Format

Share Document